Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rallybio Leverages Founders’ Experience, $145m In New Cash For Rare Diseases

Executive Summary

Former Alexion execs and Rallybio co-founders Martin Mackay, Steve Uden and Jeffrey Fryer closed a series B venture capital round to take three candidates into the clinic and acquire additional programs.

You may also be interested in...



Finance Watch: Ten IPOs In One Week Bring 2021 Total To 80

Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering. 

BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near

New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.

Cortexyme Alzheimer’s Study Fails; Drug Slows Cognitive Decline In Some Patients

Atuzaginstat targets a bacteria associated with Alzheimer’s disease. The higher of two doses showed a 57% slowing in cognitive decline in the Phase II/III GAIN trial in mild to moderate patients with P. gingivalis infection confirmed by saliva test.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel